ResMed Inc. (NYSE:RMD) CFO Brett Sandercock sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, November 30th. The stock was sold at an average price of $110.50, for a total value of $331,500.00. Following the sale, the chief financial officer now owns 101,390 shares of the company’s stock, valued at approximately $11,203,595. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Brett Sandercock also recently made the following trade(s):
- On Thursday, November 15th, Brett Sandercock sold 2,000 shares of ResMed stock. The stock was sold at an average price of $101.44, for a total value of $202,880.00.
- On Monday, October 15th, Brett Sandercock sold 2,000 shares of ResMed stock. The stock was sold at an average price of $103.16, for a total value of $206,320.00.
- On Monday, September 17th, Brett Sandercock sold 2,000 shares of ResMed stock. The stock was sold at an average price of $114.30, for a total value of $228,600.00.
RMD opened at $112.13 on Thursday. The company has a current ratio of 2.58, a quick ratio of 1.91 and a debt-to-equity ratio of 0.27. The firm has a market cap of $15.98 billion, a P/E ratio of 31.76, a P/E/G ratio of 2.86 and a beta of 1.01. ResMed Inc. has a 52 week low of $83.60 and a 52 week high of $116.64.
ResMed (NYSE:RMD) last posted its quarterly earnings data on Thursday, October 25th. The medical equipment provider reported $0.81 EPS for the quarter, beating analysts’ consensus estimates of $0.80 by $0.01. The business had revenue of $588.28 million for the quarter, compared to analyst estimates of $576.66 million. ResMed had a return on equity of 26.29% and a net margin of 13.94%. Equities analysts predict that ResMed Inc. will post 3.7 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 13th. Investors of record on Thursday, November 8th will be paid a dividend of $0.37 per share. This represents a $1.48 dividend on an annualized basis and a dividend yield of 1.32%. The ex-dividend date is Wednesday, November 7th. ResMed’s payout ratio is currently 41.93%.
RMD has been the subject of several research analyst reports. Credit Suisse Group upgraded ResMed from a “neutral” rating to an “outperform” rating in a research report on Friday, October 26th. BMO Capital Markets upped their target price on ResMed from $107.00 to $109.00 and gave the company a “market perform” rating in a report on Friday, October 26th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $114.50.
Several institutional investors and hedge funds have recently bought and sold shares of RMD. Deutsche Bank AG boosted its stake in shares of ResMed by 323.1% during the third quarter. Deutsche Bank AG now owns 1,367,475 shares of the medical equipment provider’s stock valued at $157,721,000 after acquiring an additional 1,044,295 shares during the last quarter. AQR Capital Management LLC boosted its stake in shares of ResMed by 151.5% during the third quarter. AQR Capital Management LLC now owns 889,450 shares of the medical equipment provider’s stock valued at $102,590,000 after acquiring an additional 535,803 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of ResMed by 149.1% during the third quarter. Renaissance Technologies LLC now owns 747,900 shares of the medical equipment provider’s stock valued at $86,263,000 after acquiring an additional 447,649 shares during the last quarter. Schroder Investment Management Group boosted its stake in shares of ResMed by 185.9% during the third quarter. Schroder Investment Management Group now owns 468,020 shares of the medical equipment provider’s stock valued at $53,981,000 after acquiring an additional 304,320 shares during the last quarter. Finally, BlackRock Inc. boosted its stake in shares of ResMed by 2.1% during the third quarter. BlackRock Inc. now owns 11,180,412 shares of the medical equipment provider’s stock valued at $1,289,550,000 after acquiring an additional 226,612 shares during the last quarter. 65.02% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Insider Selling: ResMed Inc. (RMD) CFO Sells 3,000 Shares of Stock” was first published by Zolmax and is owned by of Zolmax. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://zolmax.com/investing/insider-selling-resmed-inc-rmd-cfo-sells-3000-shares-of-stock/2744297.html.
ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.
Featured Article: Dollar Cost Averaging
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.